HIV-1 pre-exposure prophylaxis
Infectious disease · 2017–2023
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| cabotegravir Pre-exposure prophylaxis (PrEP) for HIV-1 infection in persons in whom tenofovir disoproxil and emtricitabine (TD/FTC) is contraindicated, or persons who are… | Sep 2023 | Deferred | 6 individuals West Australian AIDS Council · Australian Federation · National Association of People · HIV Australia |
| tenofovir disoproxil fumarate with emtricitabine Pre-exposure prophylaxis against HIV-1 in adults at medium to high risk of infection. | Jul 2017 | Deferred | 3 individuals Australian Federation · National Association of People · HIV Australia · AIDS Council · AIDS Action Council · Bobby Goldsmith Foundation · Victorian AIDS Council · Western Australian AIDS Council |
Who spoke
Australian Federation · National Association of People · HIV Australia · West Australian AIDS Council · AIDS Council · AIDS Action Council · Bobby Goldsmith Foundation · Victorian AIDS Council · Western Australian AIDS Council
What the PBS pays
$184M in government benefit over 2024–25, across 193,202 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| tenofovir disoproxil fumarate / emtricitabine | $183.6M |
| cabotegravir | $0.1M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.